Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (18,567,234)	$ (11,870,228)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	2,187,149	590,041
Changes in operating assets and liabilities:
Prepaid assets	(1,122,495)	(1,080,397)
Accounts payable	862,676	12,449
Deferred research grant revenue	24,315
Accrued research and development expense		1,132,013
Net cash used in operating activities	(16,615,589)	(11,216,122)
Cash flows from investing activities:
Purchases of property and equipment	(1,102,808)
Net cash used in investing activities	(1,102,808)
Cash flows from financing activities:
Net proceeds from issuance of common stock in connection with IPO		21,851,160
Net proceeds from issuance of preferred stock		7,198,227
Net proceeds from issuance of common stock	24,280,283
Proceeds from issuance of common stock for stock option exercises	714,382
Net cash provided by financing activities	24,994,665	29,049,387
Effect of exchange rate changes on cash and cash equivalents	(70,399)
Net increase in cash and cash equivalents	7,205,869	17,833,265
Cash and cash equivalents at beginning of year	28,094,936	10,261,671
Cash and cash equivalents at end of year	35,300,805	28,094,936
Supplemental disclosure of non-cash investing and financing activities:
Accrued dividend		875,359
Conversion of Series A Preferred Stock (including accrued dividends) to common stock		21,287,907
Offering costs netted with proceeds from IPO		97,312
Deemed dividend for beneficial conversion feature of Series A Preferred Stock		23,929,751
Cashless exercise of warrants	530
Issuance of common stock for accrued research and development expense	$ 1,132,013